Overview

The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis

Status:
Terminated
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
Emotionally labile, depressed participants with multiple sclerosis treated with escitalopram will have a greater reduction in emotional lability scores and in their psychological distress scores than those who are randomized to receive placebo.
Phase:
Phase 4
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborator:
Forest Laboratories
Treatments:
Antidepressive Agents
Citalopram
Dexetimide